Aqvesme Approved for Anemia in Alpha- or Beta-Thalassemia – Clinical Advisor

Written by

admin

in

  1. Aqvesme Approved for Anemia in Alpha- or Beta-Thalassemia  Clinical Advisor
  2. Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright  Investing.com
  3. FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia  Pharmacy Times
  4. AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T  GuruFocus
  5. FDA clears Agios’ oral PK activator for thalassaemia-linked anaemia  FirstWord Pharma

Continue Reading

More posts